Benign Prostatic Hyperplasia Surgical Treatment Market Size Worth USD 21.19 Billion by 2034 | CAGR: 5.3%

The global benign prostatic hyperplasia surgical treatment market size is expected to reach USD 21.19 billion by 2034, according to a new study by Polaris Market Research. The report “Benign Prostatic Hyperplasia Surgical Treatment Market Size, Share, Trends, Industry Analysis Report: By Type, End User (Hospitals, Ambulatory Surgery Centers and Clinics, and Homecare Settings), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The benign prostatic hyperplasia (BPH) surgical treatment market focuses on addressing the medical condition of an enlarged prostate, which often leads to symptoms such as frequent urination, urinary retention, and bladder infections. Surgical treatments for BPH are necessary when conservative therapies like medications fail to alleviate symptoms. The market has seen notable growth, driven by an increasing incidence of BPH, especially among the aging male population, who are more susceptible to prostate enlargement. The rising demand for minimally invasive procedures, such as laser-based therapies, transurethral resection of the prostate (TURP), and prostate artery embolization (PAE), is significantly contributing to the benign prostatic hyperplasia surgical treatment market expansion.

Advancements in surgical technology, which offer improved patient outcomes with shorter recovery times, reduced complications, and minimal hospital stays, is one of the key factors fueling market development. Moreover, rising awareness and diagnosis of BPH, coupled with increased healthcare access and reimbursement policies, have propelled market demand. The introduction of robotic-assisted surgeries and the growing adoption of laser surgeries are transforming the treatment landscape, providing patients with more options and driving the overall benign prostatic hyperplasia surgical treatment market growth.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/benign-prostatic-hyperplasia-surgical-treatment-market/request-for-sample

The market dynamics also include a growing preference for outpatient procedures, which has spurred innovation in surgical techniques. Additionally, rising disposable income in several regions is enabling greater access to advanced treatments. The market holds considerable opportunity for expansion as the population continues to age, with an increasing focus on patient-centric solutions. The market is also poised to witness more research and development efforts, further optimizing treatment options and promoting value-based care. Consequently, the market is expected to continue evolving, presenting promising opportunities for stakeholders involved in the healthcare industry.

Benign Prostatic Hyperplasia Surgical Treatment Market Report Highlights

• In terms of type, the laser surgeries segment accounted for a significant market share in 2024 due to their precision, minimal invasiveness, and shorter recovery time.
• Based on end user, the homecare settings segment accounted for the largest market share in 2024 due to growing patient preference for convenience and cost-effective treatment options.
• In 2024, North America accounted for the largest market share due to the high prevalence of BPH and advanced healthcare infrastructure.
• The Asia Pacific benign prostatic hyperplasia surgical treatment market is expected to witness the fastest growth during the forecast period due to increasing healthcare access and a rising elderly population.
• Some of the global key market players are Allium; Alembic Pharmaceuticals Limited; Asahi Kasei Corporation; Asclepion Laser Technologies GmbH; Boston Scientific Corporation; Coloplast Group; Cook Medical; IPG Photonics Corporation; Karl Storz Se & Co. KG; Medifocus, Inc.; Olympus Corporation; PNN Medical A/S; ProstaLund Ab; PROCEPT BioRobotics Corporation; Quanta System; Richard Wolf GmbH; SRS Medical; Teleflex Incorporated; and Urologix, LLC.

Polaris Market Research has segmented the benign prostatic hyperplasia surgical treatment market report on the basis of type, end user, and region:

By Type Outlook (Revenue, USD Billion, 2020–2034)

• Transurethral Resection of the Prostate (TURP)
• Laser Surgeries
• Urolift Procedures
• Rezum Procedures
• Robot-Assisted Waterjet Ablation
• Prostatic Stents
• Transurethral Microwave Thermotherapy (TUMT)
• Transurethral Needle Ablation of the Prostate (TUNA)
• Prostatic Arterial Embolization (PAE)
• Other Procedures

By End User Outlook (Revenue, USD Billion, 2020–2034)

• Hospitals
• Ambulatory Surgery Centers and Clinics
• Homecare Settings

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Benign Prostatic Hyperplasia Surgical Treatment Market Report Scope